Close menu




November 3rd, 2021 | 11:03 CET

MorphoSys, Defence Therapeutics, Formycon - Biotech and pharma offer potential for the portfolio

  • Biotechnology
Photo credits: pixabay.com

The pharmaceutical industry alone has annual sales of over EUR 1,000 billion worldwide and helps people overcome their illnesses. Since the Corona pandemic, biotech and pharma companies are even more in the spotlight. If a company manages to develop a blockbuster, big profits also beckon to shareholders. BioNTech is currently a prime example of this, even if the share has consolidated in the meantime. Where there are high profits, there is also a higher risk. The road to the development and approval of a drug is long, and failure is also possible. As people are getting older and diseases are rising, it makes sense to invest in these areas. Today we analyze three potential candidates.

time to read: 4 minutes | Author: Armin Schulz
ISIN: MORPHOSYS AG O.N. | DE0006632003 , DEFENCE THERAPEUTICS INC | CA24463V1013 , FORMYCON AG | DE000A1EWVY8

Table of contents:


    MorphoSys - Good news

    The former stock market darling MorphoSys owns the most extensive antibody library globally, and from this, new drugs have been developed repeatedly through collaborations. The licensing income generated in this way allowed the Company to grow, and the biotech company was to slowly become a pharmaceutical company. Since then, this major undertaking has caused difficulties within the Company. These became even greater with the decision to take over Constellation Pharmaceuticals because large parts of the licensing income were given out of hand to finance the takeover.

    Recently, the Company was able to come up with a series of good news. On October 20, it was announced that the first patient with immunoglobulin A nephropathy, a chronic kidney disease, had been treated in the course of a Phase II trial. This prompted the analysts at Berenberg to give the share a price target of EUR 124. On November 2, there was a small preview of the 3rd quarter figures, which will be presented on November 11. Compared to Q2, sales of the cancer drug Monjuvi increased by EUR 3.7 million to EUR 18.6 million.

    In addition, the Company has two drugs from Constellation Pharmaceuticals in the pipeline, which are in their phase III trials. Since October 19, the stock has risen from EUR 37.10 to EUR 42.26. To leave the downtrend, a closing price above EUR 43.25 would be necessary. That would also mean crossing the 50 moving average from the bottom to the top. The next resistance would then be at EUR 51.60.

    Defence Therapeutics - Success in the fight against breast cancer

    The Canadian biotech company Defence Therapeutics is breaking new ground in drug delivery. Whereas conventional drugs using antibody-drug conjugates (ADC) have repeatedly shown ineffective drug delivery, using the Company's proprietary Accum platform, the drug is delivered precisely to the cell nucleus that needs it. This intracellular ADC routing improves outcomes by a factor of 10, and the platform technology, which all approved ADCs can use, significantly enhances the therapeutic effect.

    The first results are available for the AccuVAC-IN002 Corona vaccine, which is administered intranasally. It was previously tested with success in mice and subsequently in rabbits. Furthermore, a program is underway to develop a vaccine against HPV to prevent cervical cancer. Since June 29, the collaboration with the Institut Curie in Paris has been ongoing to investigate the therapeutic efficacy of the Accum-T-DM1-ADC compound against breast cancer. On October 13, the Company reported that the efficacy of Accum variants of T-deruxtecan against breast cancer was improved 5-fold.

    The Company is currently preparing a Phase I trial of its cancer vaccine AccuVAC-D0002. The product pipeline is full, and the more successful trials that have been completed, the more exciting the stock becomes. It is currently at 6.10 Canadian dollars (CAD) and could form a double bottom. If that succeeds, the all-time high at CAD 8.15 should be tested. The upward trend remains intact as long as there has been no closing price below CAD 6.00. Support below this mark is at CAD 3.39. This would then close the price gap.

    Formycon - FDA reviews approval

    The biotech company Formycon develops biosimilars after patent expiry of the original drug, i.e. biological drugs as an alternative to the originals. The focus is on therapies in ophthalmology, immunology and chronic diseases. The Company sees itself as a partner for large pharmaceutical and generics companies. The Company started shortly after the outbreak of the Corona pandemic with the development of an antibody fusion protein to block cell infection by the virus completely. It is currently in preclinical development.

    A potential profit driver for the future is FYB201, the biosimilar to the eye drug Lucentis. On October 4, acceptance of FYB201 for approval by the FDA was confirmed, and approval has also been filed in Europe. The decision is expected to be made in August 2022. On October 19, a licensing and collaboration agreement was signed with SCG Cell Therapy, giving the Asian Company exclusive rights to Covid's drug FYB207 in Asia, excluding Japan. If the drug is approved in the region, up to EUR 63.5 million in one-time payments and royalties in the low double-digit percentage range of sales await.

    The Company has a broad range of drugs in the pipeline. Management and the advisory board are experts in biosimilar development. The stock has been able to attract some attention due to its research in the Corona area. If FYB201 is approved, up to EUR 100 million per year could be flushed into the Company's coffers. Since the beginning of August, the share has been moving sideways between EUR 47.00 and EUR 53.90. An upward breakout makes a test of EUR 64 likely.


    The potential of biotech and pharmaceutical companies is great. If you jump on the bandwagon too late, you will have to endure significant setbacks, as in the case of MorphoSys. If you invest early, as in the case of Defence Therapeutics, you can quickly have a multiplier in your portfolio if the Company is successful. Formycon uses existing drugs and reproduces them on a biological basis. The principle promises big profits if approved. However, the share has already started up well due to the development of a Corona drug.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Juliane Zielonka on May 12th, 2022 | 13:07 CEST

    Cardiol Therapeutics, Tesla, Bayer AG - Instead of trading chronically overvalued shares, treat the chronically ill instead

    • Biotechnology

    No sooner does the US government under Biden seek to influence the Supreme Court in the Monsanto case than the Bayer share slides 7%. But is this share price slide justified? Bayer AG has made provisions for the possible ruling in June and set aside reserves for chronic diseases. Chronic diseases are also a focus of Cardiol Therapeutics. According to the World Health Organization (WHO), the prevalence of chronic diseases increased by 57% worldwide by 2020. Cardiol focuses on heart health in this regard. The share stands at about EUR 1.12 and is seen by analysts at an average of about EUR 7. Meanwhile, Tesla investors are currently experiencing what overvalued shares can do to their portfolios. Their CEO is speculating that he will no longer accept new customers. Why? You can read about it here...

    Read

    Commented by Fabian Lorenz on May 12th, 2022 | 11:12 CEST

    BioNTech, BYD and Desert Gold: Shares for the rebound

    • Gold
    • Electromobility
    • Biotechnology

    Is the rebound coming? After the heavy price losses of recent days and weeks, the market seems ripe for a countermovement. However, this would require a little more volume in the market. But then, especially companies that have not disappointed operationally should profit. BioNTech, for example, belongs to this group. The Company has published convincing figures, and analysts see up to 50% price potential. BYD's share price should also pick up speed again. Finally, the rapid shift to electric pureplay seems to be succeeding and HSBC has raised the price target. Gold was not a safe haven in the current correction. But it is worth looking at bombed-out stocks here as well. Desert Gold Ventures is one of them. The explorer has started a new drill program and secured financing.

    Read

    Commented by Juliane Zielonka on May 10th, 2022 | 12:38 CEST

    Biotech stocks: Defence Therapeutics, BioNTech, BASF - Advantage through platform technology

    • Biotechnology

    Large corporations such as BASF were previously considered safe portfolio investments. But the war in Ukraine is throwing a spanner in the works. Force majeure, such as war, can cause deals to fall through without the responsibility of the companies involved. How should investors react now? Which portfolio strategy can keep up with the high volatility of the markets? Newcomers like BioNTech face oversupply and have to accept shortages. A focus on emerging markets seems to be the solution for their growth strategy. But there are subtle differences in the vaccines business, as Defence Therapeutics proves.

    Read